Raltegravir

• UNSPSC Description:

  Raltegravir is a potent integrase (IN) inhibitor, used to treat HIV infection.

• Target Antigen:

  HIV; HIV Integrase

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;Metabolic Enzyme/Protease

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/raltegravir.html

• Purity:

  99.93

• Solubility:

  DMSO : ≥ 100 mg/mL

• Smiles:

  O=C(C(O)=C(C(NCC1=CC=C(C=C1)F)=O)N=C2C(C)(C)NC(C3=NN=C(C)O3)=O)N2C

• Molecular Weight:

  444.42

• References & Citations:

  [1]Hare, S., et al., Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Proc Natl Acad Sci U S A, 2010. 107(46): p. 20057-62.|[2]Hicks C, et al. Raltegravir: the first HIV type 1 integrase inhibitor. Clin Infect Dis. 2009 Apr 1;48(7):931-9|[3]Moss DM, et al. Divalent metals and pH alter raltegravir disposition in vitro. Antimicrob Agents Chemother. 2012 Jun;56(6):3020-6|[4]Hare S, et al. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol. 2011 Oct;80(4):565-72.|[5]Lewis, M.G., et al. Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy. Retrovirology, 2010. 7: p. 21.|[6]Xu P, et al. Combined Medication of Antiretroviral Drugs Tenofovir Disoproxil Fumarate, Emtricitabine, and Raltegravir Reduces Neural Progenitor Cell Proliferation In Vivo and In Vitro. J Neuroimmune Pharmacol. 2017 Dec;12(4):682-692.Bioorg Med Chem. 2019 Sep 1;27(17):3836-3845. |Clin Drug Investig. 2019 Mar;39(3):285-299. |J Infect Dis. 2022 Sep 19;jiac386.|J Mol Biol. 2022 Feb 22;167507.|J Neuroimmune Pharmacol. 2017 Dec;12(4):682-692.|J Virol. 2017 Jan 18;91(3). pii: e02152-16.|Life Sci. 9 September 2022, 120948.|Molecules. 2022 Dec 12;27(24):8829.|Open Forum Infect Dis. 2024 Nov 29.|PeerJ Physical Chemistry. 2019, 1:e6.|Pharmaceuticals. 2023 Aug 8, 16(8), 1118.|Phytomedicine. 2016 Nov 15;23(12):1383-1391. |Preprints. 2024 Apr 23.|Preprints. 2024 Feb 19.|SSRN. 2023 Mar 30.|Virol Sin. 2023 May 10;S1995-820X(23)00054-8.|Virology. 2023 Jun 21.|Viruses. 2021 Jan 18;13(1):E131.|Viruses. 2024 Oct 13;16(10):1607.|Plant Biosyst. 2018, 1-8.|PLoS One. 2018 Mar 30;13(3):e0195168.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, protect from light)

• Clinical Information:

  Launched

• CAS Number:

  518048-05-0